BY-24.3

N/A

Report date: 2024/11/14 18:07:00

Base Information

Drug NameBY-24.3
Drug Alias NameBY-24.3
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionProgrammed cell death protein 1 blockersVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor AProgrammed cell death protein 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijing Biyang Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Biyang Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A